source
- T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugsT-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…
- Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemiaAlethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…